quotes from the founders:
”we’re one of the few companies really focusing on optimising the pharmacology of these first generation compounds to develop entirely new therapeutics”
”addressing the intense perceptual effects, and either reducing their duration or tempering them to make the therapies more applicable to a wider patient population”
sound familiar? Just like IHL’s modus operandi around leaning on the de-risked nature of constituent drugs, and focus on combination to not only combine different methods of action but also lower side effects.
- Forums
- ASX - By Stock
- IHL
- Industry news
Industry news, page-672
-
-
- There are more pages in this discussion • 227 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)